BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pang TC, Lam VW. Surgical management of hepatocellular carcinoma. World J Hepatol 2015; 7(2): 245-252 [PMID: 25729479 DOI: 10.4254/wjh.v7.i2.245] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 48] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Shen X, Cui X, Cui H, Jin Y, Jin W, Sun H. Geraniol and lupeol inhibit growth and promote apoptosis in human hepatocarcinoma cells through the MAPK signaling pathway. J Cell Biochem 2019;120:5033-41. [DOI: 10.1002/jcb.27779] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
2 Kaseb AO, Vence L, Blando J, Yadav SS, Ikoma N, Pestana RC, Vauthey JN, Allison JP, Sharma P. Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma. Cancer Immunol Res 2019;7:1390-5. [PMID: 31289040 DOI: 10.1158/2326-6066.CIR-18-0605] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
3 Glantzounis GK, Tokidis E, Basourakos SP, Ntzani EE, Lianos GD, Pentheroudakis G. The role of portal vein embolization in the surgical management of primary hepatobiliary cancers. A systematic review. Eur J Surg Oncol. 2017;43:32-41. [PMID: 27283892 DOI: 10.1016/j.ejso.2016.05.026] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 8.2] [Reference Citation Analysis]
4 Mazzanti R, Arena U, Tassi R. Hepatocellular carcinoma: Where are we? World J Exp Med 2016; 6(1): 21-36 [PMID: 26929917 DOI: 10.5493/wjem.v6.i1.21] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 68] [Article Influence: 12.5] [Reference Citation Analysis]
5 Arai K, Fukumoto T, Kido M, Tanaka M, Kuramitsu K, Kinoshita H, Komatsu S, Tsugawa D, Terai S, Matsumoto T, Goto T, Asari S, Toyama H, Ajiki T, Ku Y. Preoperative neutrophil-to-lymphocyte ratio as a predictor of survival after reductive surgery plus percutaneous isolated hepatic perfusion for hepatocellular carcinoma: a retrospective analysis. Surg Today. 2017;47:385-392. [PMID: 27465474 DOI: 10.1007/s00595-016-1384-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
6 Lee HW, Suh KS. Expansion of the criteria for living donor liver transplantation for hepatocellular carcinoma. Curr Opin Organ Transplant. 2016;21:231-237. [PMID: 26918880 DOI: 10.1097/mot.0000000000000294] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
7 Vasuri F, Fittipaldi S, De Pace V, Gramantieri L, Bertuzzo V, Cescon M, Pinna AD, Fiorentino M, D'Errico A, Ravaioli M. Tissue miRNA 483-3p expression predicts tumor recurrence after surgical resection in histologically advanced hepatocellular carcinomas. Oncotarget 2018;9:17895-905. [PMID: 29707155 DOI: 10.18632/oncotarget.24860] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
8 Wu X, Zhao B, Cheng Y, Yang Y, Huang C, Meng X, Wu B, Zhang L, Lv X, Li J. Melittin induces PTCH1 expression by down-regulating MeCP2 in human hepatocellular carcinoma SMMC-7721 cells. Toxicol Appl Pharmacol 2015;288:74-83. [PMID: 26189965 DOI: 10.1016/j.taap.2015.07.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
9 West CA, Black AP, Mehta AS. Analysis of Hepatocellular Carcinoma Tissue for Biomarker Discovery. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 93-107. [DOI: 10.1007/978-3-030-21540-8_5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Kabbach G, Assi HA, Bolotin G, Schuster M, Lee HJ, Tadros M. Hepatobiliary Tumors: Update on Diagnosis and Management. J Clin Transl Hepatol 2015;3:169-81. [PMID: 26623263 DOI: 10.14218/JCTH.2015.00012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
11 Tian Y, Yao W, He D, Xu Y, Li Y, Zhu Y, Fang J, Bai B, Li X, Sun L, Jin N. A dual cancer-specific recombinant adenovirus suppresses the growth of liver cancer cells in vivo and in vitro. Anticancer Drugs 2020;31:110-22. [PMID: 31658131 DOI: 10.1097/CAD.0000000000000854] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Hsu CY, Wang CW, Cheng AL, Kuo SH. Hypofractionated particle beam therapy for hepatocellular carcinoma–a brief review of clinical effectiveness. World J Gastrointest Oncol 2019; 11(8): 579-588 [PMID: 31435460 DOI: 10.4251/wjgo.v11.i8.579] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
13 Shimizu T, Ishizuka M, Suzuki T, Tanaka G, Park KH, Matsumoto T, Shiraki T, Sakuraoka Y, Kato M, Aoki T, Kubota K. The preoperative globulin-to-albumin ratio, a novel inflammation-based prognostic system, predicts survival after potentially curative liver resection for patients with hepatocellular carcinoma. J Surg Oncol 2017;116:1166-75. [PMID: 28853157 DOI: 10.1002/jso.24772] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
14 Zhang Y, Li T, Qiu Y, Zhang T, Guo P, Ma X, Wei Q, Han L. Serum microRNA panel for early diagnosis of the onset of hepatocellular carcinoma. Medicine (Baltimore). 2017;96:e5642. [PMID: 28079796 DOI: 10.1097/md.0000000000005642] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 8.6] [Reference Citation Analysis]
15 Ricci AD, Rizzo A, Bonucci C, Tavolari S, Palloni A, Frega G, Mollica V, Tober N, Mazzotta E, Felicani C, Serra C, Brandi G. The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma. In Vivo 2020;34:3421-9. [PMID: 33144450 DOI: 10.21873/invivo.12181] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
16 Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14:203-217. [PMID: 28053342 DOI: 10.1038/nrgastro.2016.193] [Cited by in Crossref: 146] [Cited by in F6Publishing: 145] [Article Influence: 29.2] [Reference Citation Analysis]
17 Qian Y, Su H, Ge Y, Lei K, Li Y, Fan H. Prognostic value of PD-L1 expression combined with hypoxia-associated immunosuppression in hepatocellular carcinoma. Biomark Med 2022. [PMID: 35212229 DOI: 10.2217/bmm-2021-1051] [Reference Citation Analysis]
18 Ju MR, Yopp AC. Evolving thresholds for liver transplantation in hepatocellular carcinoma: A Western experience. Ann Gastroenterol Surg 2020;4:208-15. [PMID: 32490334 DOI: 10.1002/ags3.12316] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Asemota J, Saleh M, Igbinovia O, Burns D. A Concise Review on Current Trends in Imaging and Surgical Management of Hepatocellular Carcinoma. Cureus 2020;12:e9191. [PMID: 32818122 DOI: 10.7759/cureus.9191] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Shen PC, Chang WC, Lo CH, Yang JF, Lee MS, Dai YH, Lin CS, Fan CY, Huang WY. Comparison of Stereotactic Body Radiation Therapy and Transarterial Chemoembolization for Unresectable Medium-Sized Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 2019;105:307-18. [PMID: 31175903 DOI: 10.1016/j.ijrobp.2019.05.066] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
21 Qi X, Schepers E, Avella D, Kimchi ET, Kaifi JT, Staveley-O'Carroll KF, Li G. An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis. J Vis Exp 2019. [PMID: 31566616 DOI: 10.3791/59368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
22 Kornberg A, Schernhammer M, Friess H. 18F-FDG-PET for Assessing Biological Viability and Prognosis in Liver Transplant Patients with Hepatocellular Carcinoma. J Clin Transl Hepatol 2017;5:224-34. [PMID: 28936404 DOI: 10.14218/JCTH.2017.00014] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
23 Zhang Y, Ding M, Chi JC, Wang T, Shi YP, Zhai B. The early evaluation of ultrasound-guided iodine-125 interstitial implants for high-risk hepatocellular carcinoma. Brachytherapy 2019;18:733-9. [PMID: 31515049 DOI: 10.1016/j.brachy.2019.05.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Arai K, Fukumoto T, Tanaka M, Kuramitsu K, Kido M, Kinoshita H, Matsumoto T, Toyama H, Asari S, Goto T, Ajiki T, Ku Y. Pathological complete response after percutaneous isolated hepatic perfusion in hepatocellular carcinoma with portal vein tumor thrombosis: a case report. Surg Case Rep 2016;2:50. [PMID: 27230652 DOI: 10.1186/s40792-016-0178-x] [Reference Citation Analysis]
25 Chu YD, Lai HY, Pai LM, Huang YH, Lin YH, Liang KH, Yeh CT. The methionine salvage pathway-involving ADI1 inhibits hepatoma growth by epigenetically altering genes expression via elevating S-adenosylmethionine. Cell Death Dis 2019;10:240. [PMID: 30858354 DOI: 10.1038/s41419-019-1486-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
26 Shen P, Huang W, Dai Y, Lo C, Yang J, Su Y, Wang Y, Lu C, Lin C. Radiomics-Based Predictive Model of Radiation-Induced Liver Disease in Hepatocellular Carcinoma Patients Receiving Stereo-Tactic Body Radiotherapy. Biomedicines 2022;10:597. [DOI: 10.3390/biomedicines10030597] [Reference Citation Analysis]
27 Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian F, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich VS, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo VT, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M. S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms. Z Gastroenterol 2022;60:e56-e130. [PMID: 35042248 DOI: 10.1055/a-1589-7568] [Reference Citation Analysis]
28 Matboli M, Shafei AE, Ali MA, Ashry AM, Kamal KM, Agag MA, Reda I, Tash EF, Ali M. circRNAs (hsa_circ_00156, hsa_circ _000224, and hsa_circ _000520) are novel potential biomarkers in hepatocellular carcinoma. J Cell Biochem. 2018;. [PMID: 30426540 DOI: 10.1002/jcb.28045] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
29 Strassburg CP. HCC-Associated Liver Transplantation - Where Are the Limits and What Are the New Regulations? Visc Med 2016;32:263-71. [PMID: 27722163 DOI: 10.1159/000446385] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
30 Yi PS, Li Y, Yan S, Wu B, Lan C, Li JS. Surgery combined with post-operative trancatheter arterial chemoembolization improves survival of intermediate hepatocellular carcinoma. Scand J Gastroenterol 2019;54:240-5. [PMID: 30880503 DOI: 10.1080/00365521.2019.1577487] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
31 Vasuri F, Visani M, Acquaviva G, Brand T, Fiorentino M, Pession A, Tallini G, D’Errico A, de Biase D. Role of microRNAs in the main molecular pathways of hepatocellular carcinoma. World J Gastroenterol 2018; 24(25): 2647-2660 [PMID: 29991871 DOI: 10.3748/wjg.v24.i25.2647] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 36] [Article Influence: 7.3] [Reference Citation Analysis]
32 Golabi P, Fazel S, Otgonsuren M, Sayiner M, Locklear CT, Younossi ZM. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine (Baltimore). 2017;96:e5904. [PMID: 28248853 DOI: 10.1097/md.0000000000005904] [Cited by in Crossref: 74] [Cited by in F6Publishing: 49] [Article Influence: 14.8] [Reference Citation Analysis]
33 Morris JS, Hassan MM, Zohner YE, Wang Z, Xiao L, Rashid A, Haque A, Abdel-Wahab R, Mohamed YI, Ballard KL, Wolff RA, George B, Li L, Allen G, Weylandt M, Li D, Wang W, Raghav K, Yao J, Amin HM, Kaseb AO. HepatoScore-14: Measures of Biological Heterogeneity Significantly Improve Prediction of Hepatocellular Carcinoma Risk. Hepatology 2021;73:2278-92. [PMID: 32931023 DOI: 10.1002/hep.31555] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
34 Kennedy OJ, Roderick P, Buchanan R, Fallowfield JA, Hayes PC, Parkes J. Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose-response meta-analysis. BMJ Open 2017;7:e013739. [PMID: 28490552 DOI: 10.1136/bmjopen-2016-013739] [Cited by in Crossref: 59] [Cited by in F6Publishing: 48] [Article Influence: 11.8] [Reference Citation Analysis]
35 Xu Y, Zuo W, Wang X, Zhang Q, Gan X, Tan N, Jia W, Liu J, Li Z, Zhou B, Zhao D, Xie Z, Tan Y, Zheng S, Liu C, Li H, Chen Z, Yang X, Huang Z. Deciphering the effects of PYCR1 on cell function and its associated mechanism in hepatocellular carcinoma. Int J Biol Sci 2021;17:2223-39. [PMID: 34239351 DOI: 10.7150/ijbs.58026] [Reference Citation Analysis]
36 Kornberg A, Witt U, Schernhammer M, Kornberg J, Ceyhan GO, Mueller K, Friess H, Thrum K. Combining 18F-FDG positron emission tomography with Up-to-seven criteria for selecting suitable liver transplant patients with advanced hepatocellular carcinoma. Sci Rep. 2017;7:14176. [PMID: 29074969 DOI: 10.1038/s41598-017-14430-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
37 Lee SH, Lee JS, Na GH, You YK, Kim DG. Immunohistochemical markers for hepatocellular carcinoma prognosis after liver resection and liver transplantation. Clin Transplant. 2017;31. [PMID: 27653235 DOI: 10.1111/ctr.12852] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
38 Ju M, Yopp AC. The Utility of Anatomical Liver Resection in Hepatocellular Carcinoma: Associated with Improved Outcomes or Lack of Supportive Evidence? Cancers (Basel) 2019;11:E1441. [PMID: 31561585 DOI: 10.3390/cancers11101441] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
39 Shang J, Xu S, Zhang J, Ran X, Bai L, Tang H. Efficacy of sorafenib in patients with hepatocellular carcinoma after resection: a meta-analysis. Oncotarget 2017;8:109723-31. [PMID: 29312642 DOI: 10.18632/oncotarget.21299] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
40 Yang JF, Zhao ZH, Zhang Y, Zhao L, Yang LM, Zhang MM, Wang BY, Wang T, Lu BC. Dual-input two-compartment pharmacokinetic model of dynamic contrast-enhanced magnetic resonance imaging in hepatocellular carcinoma. World J Gastroenterol 2016; 22(13): 3652-3662 [PMID: 27053857 DOI: 10.3748/wjg.v22.i13.3652] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
41 Nevarez NM, Yopp AC. Challenging the Treatment Paradigm: Selecting Patients for Surgical Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. J Hepatocell Carcinoma 2021;8:851-60. [PMID: 34350140 DOI: 10.2147/JHC.S291530] [Reference Citation Analysis]
42 Kim K, Kim SJ. Diagnostic test accuracies of F-18 FDG PET/CT for prediction of microvascular invasion of hepatocellular carcinoma: A meta-analysis. Clin Imaging 2021;79:251-8. [PMID: 34157501 DOI: 10.1016/j.clinimag.2021.06.015] [Reference Citation Analysis]
43 Xu ZG, Ye CJ, Liu LX, Wu G, Zhao ZX, Wang YZ, Shi BQ, Wang YH. The pretransplant neutrophil-lymphocyte ratio as a new prognostic predictor after liver transplantation for hepatocellular cancer: a systematic review and meta-analysis. Biomark Med. 2018;12:189-199. [PMID: 29327595 DOI: 10.2217/bmm-2017-0307] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
44 Chen Q, Li F, Zhong C, Zou Y, Li Z, Gao Y, Zou Q, Xia Y, Wang K, Shen F. Inflammation Score System using Preoperative Inflammatory Markers to Predict Prognosis for Hepatocellular Carcinoma after Hepatectomy: A Cohort Study. J Cancer 2020;11:4947-56. [PMID: 32742442 DOI: 10.7150/jca.45274] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 Yoon YI, Lee SG. Living Donor Liver Transplantation for Hepatocellular Carcinoma: An Asian Perspective. Dig Dis Sci 2019;64:993-1000. [PMID: 30895483 DOI: 10.1007/s10620-019-05551-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
46 Min GT, Li YM, Yao N, Wang J, Wang HP, Chen W. The pretreatment neutrophil-lymphocyte ratio may predict prognosis of patients with liver cancer: A systematic review and meta-analysis. Clin Transplant. 2018;32. [PMID: 29112283 DOI: 10.1111/ctr.13151] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
47 Black AP, Mehta AS. The search for biomarkers of hepatocellular carcinoma and the impact on patient outcome. Curr Opin Pharmacol. 2018;41:74-78. [PMID: 29772420 DOI: 10.1016/j.coph.2018.04.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
48 Wang Y, Peng C, Cheng Z, Wang X, Wu L, Li J, Huang C, Guo Q, Cai H. The prognostic significance of preoperative neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma receiving hepatectomy: A systematic review and meta-analysis. Int J Surg 2018;55:73-80. [PMID: 29787804 DOI: 10.1016/j.ijsu.2018.05.022] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 10.8] [Reference Citation Analysis]
49 Lim HJ, Chiow AKH, Lee LS, Tan SS, Goh BK, Koh YX, Chan CY, Lee SY. Novel method of intraoperative liver tumour localisation with indocyanine green and near-infrared imaging. Singapore Med J 2021;62:182-9. [PMID: 31680180 DOI: 10.11622/smedj.2019137] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
50 Xia Y, Brown ZJ, Huang H, Tsung A. Metabolic reprogramming of immune cells: Shaping the tumor microenvironment in hepatocellular carcinoma. Cancer Med 2021. [PMID: 34390203 DOI: 10.1002/cam4.4177] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
51 Tao CY, Liu WR, Jin L, Tang Z, Tian MX, Jiang XF, Wang H, Zhou PY, Fang Y, Ding ZB, Peng YF, Dai Z, Qiu SJ, Zhou J, Fan J, Shi YH. Surgical Treatment of Combined Hepatocellular-Cholangiocarcinoma is as Effective in Elderly Patients as it is in Younger Patients: A Propensity Score Matching Analysis. J Cancer 2018;9:1106-12. [PMID: 29581790 DOI: 10.7150/jca.23921] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]